December 2012 Blog Posts (32)

AEZS-108 Receives Special Protocol Assessment for Phase III Registration Trial in Endometrial Cancer

Preclinical and clinical studies with AEZS-108 (AN-152, zoptarelin doxorubicin; Aeterna Zentaris) a hybrid molecule composed of a targeted cytotoxic peptide conjugate analog designed for receptor-mediated targeted chemotherapy consisting of an Luteinizing Hormone Releasing Hormone carrier (LHRH; also known as gonadotropin-releasing hormone) linked to the cytotoxic agent …


Added by Peter Hofland, PhD on December 28, 2012 at 5:30pm — No Comments

Cancer And African American Children

Childhood cancer is rare—children with cancer account for less than 1 percent of all new cancer cases in the United States. But did you know that cancer is the second leading cause of death (after accidents) among children ages 1 to 14? It is estimated that in 2012 in the United States, more than 12,000 children (ages 0­ to 14) will be diagnosed with cancer and more than 1,300 will die from it.

But there is good news, too. Over the past 20 years, childhood cancer deaths…


Added by Editorial Team on December 27, 2012 at 6:00pm — No Comments

First Patient with Untreated High-risk Acute Myeloid Leukemia Enrolled in Phase III Trial of CPX-351

For the first time patients have been treated in a Phase III, multicenter, randomized, open-label clinical trial with CPX-351 (cytarabine:daunorubicin; Celator Pharmaceuticals) Liposome Injection vs. conventional cytarabine and daunorubicin therapy ("7+3") as first-line therapy in patients 60-75 years old with high-risk (secondary) acute myeloid leukemia.…


Added by Peter Hofland, PhD on December 26, 2012 at 4:30pm — No Comments

Study Links Higher Rates of Hodgkin Lymphoma Relapse in Pediatric Patients to Cancer Drug Shortage

A national study has, for the first time, linked the shortage of a number cancer drugs to a higher rate of relapse among children, teenagers and young adults with Hodgkin lymphoma. The patients were enrolled in a national clinical trial led by researchers at the St. Jude Children's Research Hospital, Memphis, TN, USA.

Estimated two-year cancer-free survival for patients enrolled in the study fell from 88-75% after the drug…


Added by Editorial Team on December 26, 2012 at 3:00pm — No Comments

Deferasirox Approved by European Commission for Iron Overload in Patients with Non-transfusion-dependent Thalassemia

Deferasirox (Exjade®, Novartis) is the first oral treatment approved in the EU for chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndromes. A pivotal placebo-controlled study data shows that the drug significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event rate[1]

Worldwide, at least…


Added by Editorial Team on December 21, 2012 at 5:00pm — No Comments

Study Identifies Ethnicity, Cultural and Social Issues as Barriers to Participation Unrelated Stem Cell Donation Registries

New research examining the role of race and ethnicity in an individual’s decision to become a donor for hematopoietic cell transplantation (HCT) identifies several factors associated with varied participation rates in national donor registries across racial/ethnic groups. Results of this first-of-its-kind study are published online today in Blood, the Journal of the American Society of Hematology (ASH).



Added by Editorial Team on December 20, 2012 at 10:00pm — No Comments

Experimental Cancer Treatment L-BLP25 (Stimuvax®) Did Not Meet Primary Endpoint of Improvement in Overall Survival in Pivotal Phase III Trial in Patients with Non-Small Cell Lung Cancer

The pivotal Phase III clinical trial of L-BLP25 (formerly referred to as Stimuvax®) known as START did not meet its primary endpoint of an improvement in overall survival in patients with unresectable, locally advanced stage IIIA or stage IIIB non-small cell lung cancer (NSCLC). The trial was conducted by Merck Serono, a division of Merck KGaA of Darmstadt,…


Added by Editorial Team on December 19, 2012 at 8:00pm — No Comments

New Randomized Phase II Study Evaluates OGX-427 in combination with Zytiga® in Men with Metastatic Castrate-Resistant Prostate Cancer

The PACIFIC trial, an investigator-sponsored, randomized Phase II study, will will be conducted to evaluate OGX-427 (OncoGenex) in men with metastatic castrate-resistant prostate cancer (CRPC) who are experiencing a rising Prostate-Specific Antigen or PSA while receiving abiraterone acetate (Zytiga®;Janssen Biotech, Inc/Johnson & Johnson). The aim of the study is to determine if…


Added by Editorial Team on December 19, 2012 at 7:30am — No Comments

Prostate Cancer Experts Propose Focal Therapy as a Promising New Treatment Option

Focal or tissue preserving therapy has become a topic of considerable interest among urologists and in recent years has been called a new paradigm in the treatment of prostate cancer, offering another treatment option designed to balance treatment effectiveness and quality of life.

Today, prostate cancer is recognized as the second leading cause of cancer death in men in Western Europe and the United States. More than 670,000 men are diagnosed with prostate cancer worldwide…


Added by Editorial Team on December 18, 2012 at 7:30pm — No Comments

New Drug Application for Radium Ra 223 Dichloride for the Treatment of Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases

Earlier today, Bayer HealthCare announced that it had submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the antineoplastic radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

Radium Ra 223 dichloride (radium-223), formerly referred to as radium-223 chloride, is…


Added by Editorial Team on December 14, 2012 at 4:30pm — No Comments

Positive Top Line Data Presented for Reolysin® in Randomized Phase III Study in Head and Neck Cancers

Initial positive top line data from the first endpoint in a double-blinded randomized Phase III clinical study examining Reolysin® (Reovirus Serotype 3 Dearing; Oncolytics), a proprietary formulation of the human reovirus, in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018;…


Added by Editorial Team on December 13, 2012 at 7:30pm — No Comments

Understanding Circulating Tumor Cells May Help Improve Cancer Diagnosis and Prognosis

A glass plate with a nanoscale roughness could be a simple way for scientists to capture and study the circulating tumor cells (CTC) that carry cancer around the body through the bloodstream (illustration). Engineering and medical researchers at the …


Added by Editorial Team on December 12, 2012 at 6:30pm — No Comments

Data for Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Not Received Chemotherapy Published in NEJM

Abiraterone acetate (Zytiga®; Janssen Research & Development, LLC) is an androgen biosynthesis inhibitor that inhibits CYP17 and improves overall survival (OS) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC).

The primary objective of COU-AA-302, a Phase III, randomized, placebo-controlled study, was to compare clinical benefit of abiraterone acetate + prednisone (P) vs placebo (PL) + P in…


Added by Editorial Team on December 12, 2012 at 6:30pm — No Comments

Ruxolitinib-data Shows Significantly Reduced Myelofibrosis Disease Burden and Suggest Overall Survival Advantage

Long-term follow-up data from the COMFORT-I and COMFORT-II Phase III studies in myelofibrosis show that ruxolitinib (INC424/Jakafi®/Jakavi®; Incyte Pharmaceuticals/Novartis) treatment resulted in sustained reductions in spleen size, a hallmark of myelofibrosis,…


Added by Editorial Team on December 11, 2012 at 6:00pm — No Comments

Updated Results for BTK Inhibitor Ibrutinib (PCI-32765) Shows Prolonged Progression Free Survival in High Risk, Advanced CLL/SLL and MCL Patients

Clinical and pre-clinical data presented at the 54th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA, December 8 - 11, 2012, demonstrates that the investigational agent PCI-32765 (ibrutinib; Pharmacyclics®) offers prolonged progression free survival with a manageable and predictable safety profile in high unmet need indications in relapsed and refractory, high risk, advanced CLL/SLL and MCL patients and…


Added by Peter Hofland, PhD on December 11, 2012 at 2:30pm — No Comments

New CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Anti-tumor Activity in Multi-Drug Resistant Human AML

Preclinical data from SGN-CD33A (Seattle Genetics, Inc), a novel CD33-directed antibody-drug conjugate (ADC) in development for the treatment of acute myeloid leukemia (AML) presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA shows that the trial drug induced CD33-specific activity at low doses in a broad panel of AML cell lines and…


Added by Editorial Team on December 11, 2012 at 2:30am — No Comments

Trial Results of Quizartinib in Patients with Relapsed and Refractory AML Shows Encouraging Results

Results from a completed Phase II study with the investigational FLT3 inhibitor, quizartinib (AC220; Astellas Pharma/Ambit Biosciences) as an oral monotherapy treatment regimen in patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) were presented earlier today at the 54th Annual Meeting of the American Society of Hematology (ASH).

The Phase II ACE study recruited patients into two separate cohorts of…


Added by Editorial Team on December 10, 2012 at 4:30pm — No Comments

Long-term Phase III Data Show Ph+ CML Patients Treated with Nilotinib Achieved Significantly Deeper Molecular vs. Patients Treated with Imatinib Mesylate

The latest results from two Phase III clinical trials establish the benefits of nilotinib (Tasigna®, Novartis) compared to imatinib mesylate tablets (Gleevec®, Novartis) in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in newly diagnosed patients and in those with residual disease who switched to nilotinib after…


Added by Editorial Team on December 10, 2012 at 4:30pm — No Comments

Targeted Molecular Therapy for Untreatable Neurofibromatosis 1 (NF1) Tumors Identified

Researchers conducting a preclinical study in mice successfully used targeted molecular therapy to block mostly untreatable nerve tumors that develop in people with the genetic disorder Neurofibromatosis 1 (NF1). Scientists from Cincinnati Children's Hospital Medical Center report their findings online December 10, 2012 in the Journal of Clinical…


Added by Editorial Team on December 10, 2012 at 8:30am — No Comments

Sanofi's Selective JAK2 inhibitor (SAR302503) Meets Primary Endpoint in Phase II Trial

New Phase II data shows that treatment with a novel, investigational, selective JAK2 inhibitor (SAR302503) reduced spleen size and improved constitutional symptoms in patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), a hematologic malignancy with unmet medical needs.[1]

The data were presented today during the Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA.,…


Added by Editorial Team on December 9, 2012 at 11:30pm — No Comments

Monthly Archives














Register for free to view all the Onco'Zine - The International Oncology Network content:


Onco'Zine is present here

Bookmark / Share



© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+